Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | 225Ac-SSO110 |
| Trade Name | |
| Synonyms | 225AcSSO110|[225Ac]Ac-SSO110 |
| Drug Descriptions |
225Ac-SSO110 is a radioconjugate comprising the alpha-radiation emitting radionuclide actinium-225 linked to the somatostatin receptor 2 (SSTR2) antagonist SSO110 (DOTA-JR11), which delivers radiation to SSTR2-expressing tumor cells, potentially resulting in decreased tumor growth (Journal of Nuclear Medicine June 2024, 65 (supplement 2) 242038). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| 225Ac-SSO110 | 225Ac-SSO110 | 0 | 0 |
| 225Ac-SSO110 + Atezolizumab | 225Ac-SSO110 Atezolizumab | 0 | 1 |
| 225Ac-SSO110 + Avelumab | 225Ac-SSO110 Avelumab | 0 | 1 |
| 225Ac-SSO110 + Durvalumab | 225Ac-SSO110 Durvalumab | 0 | 1 |
| 225Ac-SSO110 + Pembrolizumab | 225Ac-SSO110 Pembrolizumab | 0 | 1 |
| 225Ac-SSO110 + Retifanlimab | 225Ac-SSO110 Retifanlimab | 0 | 1 |